Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Solifenacin versus oxybutynin for urinary symptoms in multiple sclerosis
IRCT20190217042727N1Phase 3Completed
- Sponsor
- Kermanshah University of Medical Sciences
- Start
- Jun 2019
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, single-blind trial of solifenacin and oxybutynin in neurogenic bladder and overactive bladder (OAB) (2 arms), sponsored by Kermanshah University of Medical Sciences. Primary endpoint: Severity of urinary symptoms. Started Jun 2019; status: completed.
02
Drugs
solifenacinoxybutynin
03
Conditions
neurogenic bladderoveractive bladder (OAB)
Beyond the preview
Go deeper on IRCT20190217042727N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20190217042727N1.